← Oncology Approval Tracker

FDA DECISION ·

Blincyto

blinatumomab · Amgen

Traditional approvalTraditional conversionAcute lymphoblastic leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children with CD19-positive B-cell precursor ALL in first or second complete remission and measurable residual disease of at least 0.1%.

LAMPGEN ANALYSIS

Why it matters

The action converted the MRD-positive remission indication to traditional approval.

What research teams should watch

Verify the MRD assay and remission number and document the infusion, neurologic and cytokine release monitoring requirements.

PRIMARY RECORDS

Sources